Chemist to be next president of US science organisation


The next president-elect of the US science organisation the American Association for the Advancement of Science (AAAS) will be Geraldine Richmond, a chemist at the University of Oregon. Gerald Fink, a professor of genetics at the Massachusetts Institute of Technology, will begin his one-year term as president of the AAAS in February.

Richmond’s research interests centre around surface chemistry and its uses in environmental remediation, self-assembly, atmospheric chemistry and energy alternatives. She has served on several US government scientific advisory boards and currently sits on the National Science Board, which governs the National Science Foundation and advises the US president and Congress. Richmond also founded and chairs COACh, an organisation that aims to help women succeed in the sciences and engineering in the US and developing countries. She earned her PhD at the University of California, Berkeley, where her supervisor was George Pimentel, perhaps best known for his invention of the chemical laser.


Related Content

First science envoys announced for the US

11 December 2014 News and Analysis

news image

Former NOAA chief will serve as one of several top scientists in newly created posts

Enabling Africa's women

14 August 2013 Educated Chemist

news image

US project Coach is supporting African women to progress in science careers, Hayley Birch learns

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent